REPLIMUNE GROUP, INC. (REPL) Profit Breakdown
- 2026-06-30: Reportable -$1.52M.
- 2025-06-30: Reportable $3.73M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2017-03-31 to 2026-06-30
- Data captured
Profit by product
Nonoperating Income (Expense): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$1.52M |
| 2025-06-30 | $3.73M |
Operating income: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$68.25M |
| 2025-06-30 | -$90.42M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |